Mekhail, Tarek External Entity

Publications

Sort by

Selected publications

  • Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.  The Lancet. Oncology2016 Academic Article GET IT
    Times cited: 109

Other